News

Pharmaceutical Reverse Osmosis System: Technological Innovation Drives Efficiency Leap in Pharmaceutical Water Treatment

May 28, 2025 Leave a message

With the continuous upgrades to pharmaceutical water standards in the Chinese Pharmacopoeia (ChP), traditional ion exchange methods have struggled to meet the comprehensive demands of modern pharmaceutical processes for water purity, stability, and cost-effectiveness. Leveraging its self-developed ceramic membrane technology and all-membrane process system, Taho Environmental Protection has established a full-chain Reverse osmosis pharmaceuticals covering pretreatment, reverse osmosis, and concentrate reuse. This system provides pharmaceutical enterprises with a high-efficiency and sustainable solution.

 

Reverse Osmosis Pharmaceuticals

 

Technological Breakthrough: Ceramic Membrane Technology Redefines Pretreatment

 

In the pretreatment stage of pharmaceutical reverse osmosis plant, Taho Environmental Protection innovatively employs nano-composite ceramic membrane technology . By optimizing material ratios and sintering processes, the ceramic membrane achieves a 99.8% suspended solids rejection rate and 0.1μm filtration precision. Compared to traditional polymeric membranes, its anti-fouling capability improves by 40%, with acid/alkali resistance expanding to pH 1–14, effectively addressing membrane fouling caused by colloids, microorganisms, and other impurities in raw water. This advancement extends RO membrane cleaning cycles from weekly to quarterly, reducing system operating costs by over 30% .

 

All-Membrane Process: Achieving Zero Liquid Discharge

 

To tackle the challenge of RO concentrate treatment, Taho Environmental Protection's "All-Membrane Process for RO Concentrate and Circulating Wastewater Treatment" adopts a three-stage "ceramic ultrafiltration (UF) + high-pressure RO + electrodialysis (ED)" system . This technology elevates concentrate recovery rates to over 95%, with treated water total dissolved solids (TDS) consistently below 10 mg/L. Recognized in the National Water Resources Ministry's Key Promotion Catalog , the system has reduced energy consumption per ton of water treatment by 45% in projects like Qilu Pharmaceutical.

 

Intelligent Control: Ensuring Water Quality Stability

 

Taho Environmental Protection equips RO system in pharmaceutical industry with a DCS (Distributed Control System) , which dynamically adjusts membrane flux and recovery rates by monitoring 12 core parameters-including pressure, conductivity, and pH-in real time. The embedded AI algorithm predicts membrane fouling trends and initiates pulsed cleaning protocols preemptively, confining product water quality fluctuations to within ±5%. The upgraded 2023 IoT platform further enables remote fault diagnosis, significantly shortening equipment downtime.

 

Continuous Innovation: R&D Investment Fuels Technological Iteration

 

Over the past three years, Taho Environmental Protection has intensified R&D in high-flux ceramic membranes, developing a proprietary graded-pore structure ceramic ultrafiltration membrane with a flux of 800 L/(m²·h)-triple that of conventional products. By 2025, the company has secured 14 invention patents, including its "Tubular Ceramic Ultrafiltration Membrane Filter for Water Treatment," certified as a Shandong Province's First (Set) Key Core Component .

 

Industry Recognition: Dual Endorsement of Quality and Service

 

Taho Environmental Protection's pharmaceutical reverse osmosis plant has obtained ISO 9001 (Quality Management), ISO 14001 (Environmental Management), and OHSAS 18001 (Occupational Health and Safety Management) system certifications . It has been awarded Shandong Province's "Gazelle Enterprise" and "Specialized, Sophisticated, Distinctive, and Innovative Enterprise" titles. The company's *Technical Specifications for All-Membrane Treatment of Pharmaceutical Water* has become an industry benchmark, while its innovations were recognized in the 2024 Shandong Industrial Green and Low-Carbon Technology Equipment Certification .

 

Conclusion

 

In the era of pharmaceutical industry intelligence and decarbonization, Taho Environmental Protection's advancements in Reverse osmosis pharmaceuticals not only address the global challenge of high-salinity wastewater treatment but also establish a closed-loop system from water purification to resource recovery. With declining ceramic membrane material costs and cross-industry large-scale applications, this 27-year water treatment leader is redefining the value boundaries of pharmaceutical water management.

Send Inquiry